BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines reimbursement Expense — Research & Development ($M) ($M)
Form 10-Q / 10-K Collaborative Arrangements Note (XBRL)
Latest, FY2025
3.10
Period ended Dec 31, 2025
Change on a year earlier
+29.2%
2.40 in FY2024
History
6 years
Since FY2020
Sources
4
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Reimbursement Expense — Research & Development ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.10 | +29.2% | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 2.40 | -241.2% | Form 10-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | -1.70 | -241.7% | Form 10-K (filed 2026-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 1.20 | -400.0% | Form 10-K (filed 2025-02-27) ↗ |
| FY2021 | Dec 31, 2021 | -0.40 | -157.1% | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 0.70 | – | Form 10-K (filed 2023-02-27) ↗ |
Cite this data
StockData. (2026). BeOne Medicines Reimbursement Expense — Research & Development ($M) ($M), annual FY2020–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/reimb_rd
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.